Last reviewed · How we verify
AAVB-081
At a glance
| Generic name | AAVB-081 |
|---|---|
| Sponsor | AAVantgarde Bio Srl |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AAVB-081 CI brief — competitive landscape report
- AAVB-081 updates RSS · CI watch RSS
- AAVantgarde Bio Srl portfolio CI